NST-6179 for liver disease from intestinal failure in adults
Part of Digestive system clinical trials.
This Phase 2 study tests NST-6179 in people who have intestinal failure–associated liver disease (IFALD). It aims to improve liver function and overall outcomes for people whose liver inflammation and lab tests have been abnormal for at least 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 16 or older when you sign consent
- Have had nutrition through an IV (parenteral supplementation) for at least 6 months
- Have a diagnosis of IFALD with abnormal liver blood tests (and/or high bilirubin) for at least 6 months
- Your liver blood tests and screening labs must fit “stable liver disease” and not severe liver failure (no cirrhosis)
- Recent screening should show no other reason for liver disease (not viral, autoimmune, metabolic, or alcohol-related)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This trial tests a new drug, ALN-PNP, alone or with tirzepatide in people with a specific genetic type of fatty liver disease. It aims to see if the combination reduces liver fat.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This trial tests whether a new drug, GSK4532990, is safe and effective compared to a placebo in adults aged 18 to 70 with liver disease caused by alcohol use. The study aims to see if the drug can help treat advanced chronic liver disease.
This study tests an experimental drug called SNP-610 for a liver condition called NASH (fatty liver with inflammation). The goal is to see if the drug helps improve liver health compared to a placebo.
This trial tests an experimental drug for people with severe alcoholic hepatitis that did not improve with steroids. Participants should have a moderate level of organ failure, but not require a breathing tube or kidney dialysis.
Hear when a new Intestinal Failure Associated Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.